# SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

> **NCT02057107** · PHASE2 · COMPLETED · sponsor: **Heath Skinner** · enrollment: 40 (actual)

## Conditions studied

- Previously-Irradiated
- Squamous Cell Carcinoma of the Head and Neck Cancer

## Interventions

- **RADIATION:** SBRT
- **DRUG:** Cetuximab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02057107
- **Lead sponsor:** Heath Skinner
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-03
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057107, "SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02057107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*